Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov;26(11):904-905.
doi: 10.1002/onco.13920. Epub 2021 Sep 1.

Nature versus Nurture: Investigating Racial Disparity in Advanced Prostate Cancer

Nishita Tripathi  1 , Neeraj Agarwal  1 , Abhishek Tripathi  2
Affiliations

Nature versus Nurture: Investigating Racial Disparity in Advanced Prostate Cancer

Nishita Tripathi et al. Oncologist. 2021 Nov.

Abstract

Considering recently published studies, this commentary addresses racial inequality in cancer care for patients with prostate cancer.

PubMed Disclaimer

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

References

    1. Cross CK, Shultz D, Malkowitz SB et al. Impact of race on prostate‐specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate. J Clin Oncol 2002;20:2863–2368. - PubMed
    1. Hoffman RM, Gilliland FD, Eley JW et al. Racial and ethnic differences in advanced‐stage prostate cancer: The Prostate Cancer Outcomes Study. J Natl Cancer Inst 2001;93:388–395. - PubMed
    1. Surveillance, Epidemiology, and End Results Program Prostate cancer: recent trends in U.S. mortality rates, 2000‐2015 by race/ethnicity. Available from: https://seer.cancer.gov/statfacts/html/prost.html. Accessed August, 2021.
    1. Armstrong AJ, Szmulewitz RZ, Petrylak DP et al. ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone‐sensitive prostate cancer. J Clin Oncol 2019;37:2974–2986. - PMC - PubMed
    1. Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration‐sensitive prostate cancer. N Engl J Med 2019;381:13–24. - PubMed